HRP20210082T1 - Postupci prevencije kardiovaskularnih događaja u populacijama sa dislipidemijom sa rezidualnim rizikom - Google Patents
Postupci prevencije kardiovaskularnih događaja u populacijama sa dislipidemijom sa rezidualnim rizikom Download PDFInfo
- Publication number
- HRP20210082T1 HRP20210082T1 HRP20210082TT HRP20210082T HRP20210082T1 HR P20210082 T1 HRP20210082 T1 HR P20210082T1 HR P20210082T T HRP20210082T T HR P20210082TT HR P20210082 T HRP20210082 T HR P20210082T HR P20210082 T1 HRP20210082 T1 HR P20210082T1
- Authority
- HR
- Croatia
- Prior art keywords
- patient
- day
- cardiovascular
- concentration
- composition
- Prior art date
Links
- 230000007211 cardiovascular event Effects 0.000 title claims 8
- 230000001258 dyslipidemic effect Effects 0.000 title 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 6
- 201000001320 Atherosclerosis Diseases 0.000 claims 5
- 230000002526 effect on cardiovascular system Effects 0.000 claims 5
- 230000009885 systemic effect Effects 0.000 claims 5
- ZHKNLJLMDFQVHJ-RUZDIDTESA-N (2r)-2-[3-[[1,3-benzoxazol-2-yl-[3-(4-methoxyphenoxy)propyl]amino]methyl]phenoxy]butanoic acid Chemical compound CC[C@H](C(O)=O)OC1=CC=CC(CN(CCCOC=2C=CC(OC)=CC=2)C=2OC3=CC=CC=C3N=2)=C1 ZHKNLJLMDFQVHJ-RUZDIDTESA-N 0.000 claims 4
- 206010002388 Angina unstable Diseases 0.000 claims 4
- 208000032382 Ischaemic stroke Diseases 0.000 claims 4
- 108010028554 LDL Cholesterol Proteins 0.000 claims 4
- 208000007814 Unstable Angina Diseases 0.000 claims 4
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 4
- 229950009401 pemafibrate Drugs 0.000 claims 4
- 230000000250 revascularization Effects 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 3
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 3
- 108010023302 HDL Cholesterol Proteins 0.000 claims 3
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 3
- 229960005370 atorvastatin Drugs 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 229960000672 rosuvastatin Drugs 0.000 claims 3
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 3
- 229960002855 simvastatin Drugs 0.000 claims 3
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (10)
1. Kompozicija koja sadrži terapijski efikasnu količinu pemafibrata ili njegove farmaceutski prihvatljive soli i po izboru farmaceutski prihvatljiv nosač ili ekscipijens, za primjenu u postupku prevencije pojave kardiovaskularnih događaja kod pacijenta sa jednim ili više faktora kardiovaskularnog rizika, pri čemu:
a) pacijent ima dijabetes melitus tipa 2;
b) pacijent ima natašte TG koncentraciju ≥ 200 mg/dL i < 500 mg/dL;
c) pacijent ima HDL-C koncentraciju ≤ 40 mg/dL;
d) pacijent je:
i) na istovremenoj terapiji statinom umjerenog do visokog intenziteta;
ii) na istovremenoj terapiji za snižavanje lipida koja nije istovremena terapija statinom umjerenog do visokog intenziteta i ima LDL-C koncentraciju ≤ 70 mg/dL; ili
iii) netolerantan na statin i ima LDL-C koncentraciju ≤ 100 mg/dL;
e) pacijent je starosti 50 godina ili više ako je muškarac ili 55 godina ako je žena bez sistemske ateroskleroze, ili je sa sistemskom aterosklerozom;
f) terapijski efikasna količina pemafibrata ili njegove farmaceutski prihvatljive soli je 0.4 mg, administrirana oralno na dan; i
g) kardiovaskularni događaji su odabrani od nefatalnog infarkta miokarda, nefatalnog ishemijskog moždanog udara, hospitalizacije zbog nestabilne angine koja zahtjeva neplaniranu koronarnu revaskularizaciju, kardiovaskularne smrti ili njihove kombinacije.
2. Kompozicija za primjenu prema patentnom zahtjevu 1, pri čemu pacijent istovremeno uzima statine odabrane od atorvastatina ≥ 40 mg/dan, rosuvastatina ≥ 20 mg/dan i simvastatina ≥ 40 mg/dan.
3. Kompozicija za primjenu prema patentnom zahtjevu 1 ili 2, pri čemu pacijent nema sistemsku aterosklerozu.
4. Kompozicija za primjenu prema patentnom zahtjevu 1, 2 ili 3, pri čemu su kardiovaskularni događaji odabrani od nefatalnog ishemijskog moždanog udara, hospitalizacije zbog nestabilne angine koja zahtjeva neplaniranu koronarnu revaskularizaciju, kardiovaskularne smrti ili njihove kombinacije.
5. Kompozicija koja sadrži terapijski efikasnu količinu pemafibrata ili njegove farmaceutski prihvatljive soli i po izboru farmaceutski prihvatljiv nosač ili ekscipijens, za primjenu u liječenju kardiovaskularne bolesti ili prevenciju neželjenih kardiovaskularnih događaja kod pacijenta sa dijabetes melitusom tipa 2, pri čemu pacijent ima:
a) natašte TG koncentraciju ≥ 200 mg/dL i < 500 mg/dL;
b) HDL-C koncentraciju ≤ 40 mg/dL; i
c) kontrolirane LDL-C nivoe;
pri čemu pacijent nema sistemsku aterosklerozu.
6. Kompozicija za primjenu prema patentnom zahtjevu 5, naznačena time što pacijent istovremeno uzima statine odabrane od atorvastatina ≥ 40 mg/dan, rosuvastatina ≥ 20 mg/dan i simvastatina ≥ 40 mg/dan.
7. Kompozicija za primjenu prema patentnom zahtjevu 5 ili 6, pri čemu su kardiovaskularni događaji odabrani od nefatalnog ishemijskog moždanog udara, hospitalizacije zbog nestabilne angine koja zahtjeva neplaniranu koronarnu revaskularizaciju, kardiovaskularne smrti ili njihove kombinacije.
8. Kompozicija koja sadrži terapijski efikasnu količinu pemafibrata ili njegove farmaceutski prihvatljive soli i po izboru farmaceutski prihvatljiv nosač ili ekscipijens, za primjenu u liječenju kardiovaskularne bolesti ili prevenciji neželjenih kardiovaskularnih događaja kod pacijenta sa dijabetes melitusom tipa 2, pri čemu pacijent ima:
a) natašte TG koncentraciju ≥ 200 mg/dL i < 500 mg/dL;
b) HDL-C koncentraciju ≤ 40 mg/dL; i
c) kontrolirane LDL-C nivoe;
pri čemu pacijent istovremeno uzima statine odabrane od atorvastatina ≥ 40 mg/dan, rosuvastatina ≥ 20 mg/dan, i simvastatina ≥ 40 mg/dan.
9. Kompozicija za primjenu prema patentnom zahtjevu 8, pri čemu pacijent nema sistemsku aterosklerozu.
10. Kompozicija za primjenu prema patentnom zahtjevu 8 ili 9, pri čemu su kardiovaskularni događaji odabrani od nefatalnog ishemijskog moždanog udara, hospitalizacije zbog nestabilne angine koja zahtjeva neplaniranu koronarnu revaskularizaciju, kardiovaskularne smrti ili njihove kombinacije.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662368245P | 2016-07-29 | 2016-07-29 | |
| US201762462574P | 2017-02-23 | 2017-02-23 | |
| EP17183806.3A EP3275438B2 (en) | 2016-07-29 | 2017-07-28 | Methods of preventing cardiovascular events in residual risk dyslipidemic populations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210082T1 true HRP20210082T1 (hr) | 2021-03-05 |
Family
ID=59506076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210082TT HRP20210082T1 (hr) | 2016-07-29 | 2021-01-18 | Postupci prevencije kardiovaskularnih događaja u populacijama sa dislipidemijom sa rezidualnim rizikom |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US10864198B2 (hr) |
| EP (2) | EP3791872A1 (hr) |
| CY (1) | CY1123833T1 (hr) |
| DK (1) | DK3275438T3 (hr) |
| ES (1) | ES2847168T5 (hr) |
| HR (1) | HRP20210082T1 (hr) |
| HU (1) | HUE053081T2 (hr) |
| LT (1) | LT3275438T (hr) |
| PL (1) | PL3275438T3 (hr) |
| PT (1) | PT3275438T (hr) |
| RS (1) | RS61403B1 (hr) |
| SI (1) | SI3275438T1 (hr) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ624963A (en) | 2009-04-29 | 2016-07-29 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| BRPI1011876B1 (pt) | 2009-04-29 | 2020-03-31 | Amarin Pharma, Inc. | Composições farmacêuticas estáveis compreendendo etilácido eicosapentaenoico (etil-epa) e uso das mesmas para tratar ou prevenir uma doença relacionada ao cardiovascular |
| CN102625847A (zh) | 2009-06-15 | 2012-08-01 | 阿马里纳制药公司 | 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法 |
| AU2010298222B2 (en) | 2009-09-23 | 2017-01-05 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
| AU2011336856A1 (en) | 2010-11-29 | 2013-07-04 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US20130131170A1 (en) | 2011-11-07 | 2013-05-23 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| ES2891473T3 (es) | 2012-01-06 | 2022-01-28 | Amarin Pharmaceuticals Ie Ltd | Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto |
| SG10201913645RA (en) | 2012-06-29 | 2020-03-30 | Amarin Pharmaceuticals Ie Ltd | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
| WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
| US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| US10966951B2 (en) | 2017-05-19 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
| US11446282B2 (en) | 2017-12-21 | 2022-09-20 | Kowa Company, Ltd. | Methods of treating mixed dyslipidemia and hypertriglycertdemia |
| WO2019126597A1 (en) * | 2017-12-21 | 2019-06-27 | Kowa Company, Ltd. | Methods of treatment of hypertrigl yceridemia |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| WO2019216313A1 (ja) * | 2018-05-08 | 2019-11-14 | 国立大学法人岡山大学 | 心血管疾患に有用な医薬 |
| TN2021000028A1 (en) * | 2018-08-17 | 2022-10-03 | Amarin Pharmaceuticals Ie Ltd | Methods of reducing the need for peripheral arterial revascularization in a statin-treated subject |
| MA51765A (fr) | 2018-09-24 | 2020-12-16 | Amarin Pharmaceuticals Ie Ltd | Procédés de réduction du risque d'événements cardiovasculaires chez un sujet |
| US20220096443A1 (en) * | 2018-12-27 | 2022-03-31 | Kowa Company, Ltd. | Pharmaceutical composition |
| TW202038906A (zh) * | 2018-12-27 | 2020-11-01 | 日商興和股份有限公司 | 醫藥品 |
| CA3056663C (en) * | 2019-04-05 | 2022-10-18 | Jeffrey S. RIESMEYER | Use of dulaglutide in reducing risk of cardiovascular events in patients with type 2 diabetes mellitus |
| US11986452B2 (en) | 2021-04-21 | 2024-05-21 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
| TW202408500A (zh) * | 2022-07-15 | 2024-03-01 | 日商興和股份有限公司 | 血中ｌｄｌ膽固醇降低劑 |
| WO2024167964A1 (en) * | 2023-02-08 | 2024-08-15 | Kowa Company, Ltd. | Methods of treating and preventing peripheral artery disease |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1661890T3 (pl) | 2003-09-03 | 2011-06-30 | Kowa Co | Związek aktywujący PPAR oraz kompozycja farmaceutyczna zawierająca ten związek |
| TWI407955B (zh) * | 2007-03-29 | 2013-09-11 | Kowa Co | 高脂血症之預防及／或治療劑 |
-
2017
- 2017-07-28 PL PL17183806T patent/PL3275438T3/pl unknown
- 2017-07-28 ES ES17183806T patent/ES2847168T5/es active Active
- 2017-07-28 RS RS20210090A patent/RS61403B1/sr unknown
- 2017-07-28 DK DK17183806.3T patent/DK3275438T3/da active
- 2017-07-28 EP EP20203921.0A patent/EP3791872A1/en active Pending
- 2017-07-28 EP EP17183806.3A patent/EP3275438B2/en active Active
- 2017-07-28 HU HUE17183806A patent/HUE053081T2/hu unknown
- 2017-07-28 LT LTEP17183806.3T patent/LT3275438T/lt unknown
- 2017-07-28 PT PT171838063T patent/PT3275438T/pt unknown
- 2017-07-28 SI SI201730602T patent/SI3275438T1/sl unknown
- 2017-07-30 US US15/663,784 patent/US10864198B2/en active Active
- 2017-07-30 US US15/663,787 patent/US10869859B2/en active Active
-
2020
- 2020-11-11 US US17/095,327 patent/US20210085652A1/en not_active Abandoned
- 2020-11-16 US US17/099,366 patent/US20210069158A1/en not_active Abandoned
- 2020-11-16 US US17/099,167 patent/US20210077467A1/en not_active Abandoned
-
2021
- 2021-01-18 HR HRP20210082TT patent/HRP20210082T1/hr unknown
- 2021-01-21 CY CY20211100047T patent/CY1123833T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20210085652A1 (en) | 2021-03-25 |
| EP3275438B2 (en) | 2023-09-13 |
| ES2847168T5 (es) | 2024-02-20 |
| US20180028505A1 (en) | 2018-02-01 |
| US20210077467A1 (en) | 2021-03-18 |
| LT3275438T (lt) | 2021-03-25 |
| US20180028506A1 (en) | 2018-02-01 |
| US10869859B2 (en) | 2020-12-22 |
| PL3275438T3 (pl) | 2021-05-17 |
| PT3275438T (pt) | 2021-01-25 |
| EP3275438A1 (en) | 2018-01-31 |
| ES2847168T3 (es) | 2021-08-02 |
| SI3275438T1 (sl) | 2021-05-31 |
| DK3275438T3 (da) | 2021-01-18 |
| EP3275438B1 (en) | 2020-10-28 |
| CY1123833T1 (el) | 2022-05-27 |
| EP3791872A1 (en) | 2021-03-17 |
| US20210069158A1 (en) | 2021-03-11 |
| HUE053081T2 (hu) | 2021-06-28 |
| US10864198B2 (en) | 2020-12-15 |
| RS61403B1 (sr) | 2021-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210082T1 (hr) | Postupci prevencije kardiovaskularnih događaja u populacijama sa dislipidemijom sa rezidualnim rizikom | |
| KR910002794A (ko) | 〔R-(R*,R*)〕-2-(4-플루오로페닐)β,σ-디히드록시-5-1-(1-메틸에틸)-3-페닐-4〔페닐아미노)카르보닐〕-1H-피롤-1헵탄산, 그의 락톤형 및 염류 | |
| EA202190547A1 (ru) | Способы снижения потребности в реваскуляризации периферических артерий у субъекта, получающего лечение статинами | |
| WO2005034908A3 (en) | A solid dosage form comprising a fibrate and a statin | |
| HRP20170624T1 (hr) | Derivat piridina i pirazina za liječenje kronične opstrukcijske plućne bolesti | |
| JP2022116083A5 (hr) | ||
| EA199700267A1 (ru) | Применение фумагиллола и его производных для приготовления антиинфекционных интестинальных препаратов и фармацевтическая композиция на их основе | |
| BR0206968A (pt) | Ciclobuteno-1,2-dionas 3,4-dissubstituìdas como antagonistas receptores de quimiocina cxc | |
| NZ599061A (en) | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same | |
| HUP0301325A2 (hu) | Stabilizált, gyógyászatilag hatékony kompozíció és ezt tartalmazó gyógyszerkészítmény és eljárás a kompozíció előállítására | |
| RU2018140900A (ru) | Семаглутид при сердечно-сосудистых состояниях | |
| PE20020340A1 (es) | Composicion farmaceutica que comprende ester etilico de acido [2r,4s]-4-[(3,5-bis-trifluorometilbencil)metoxicarbonilamino]-2-etil-6-trifluorometil-3,4-dihidro-2h-quinolina-1-carboxilico y atorvastatina o sus metabolitos hidroxilicos | |
| ME00545B (me) | Terapeutske kombinacije koje sadrže amlodipin i atorvastatin | |
| NZ727849A (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
| HRP20100080T1 (hr) | Kombinacija koja sadrži kandesartan i rosuvastatin za liječenje ateroskleroze | |
| SG143982A1 (en) | Pharmaceutical compositions of amlodipine and atorvastatin | |
| LV10050A (lv) | Farmaceitiska kompozicija ar zemam orala antikoagulanta un trombocitu inhibitora devam | |
| CA2487297A1 (en) | The use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases | |
| AR025307A1 (es) | Compuesto de liberacion sostenida de un peptido, microparticulas, composicion farmaceutica y el uso de dicho compuesto para la fabricacion de un medicamento | |
| BR0313220A (pt) | Pelìcula de revestimento para comprimidos e cápsulas | |
| JP2019533715A5 (hr) | ||
| WO2003024943A3 (en) | Aryl derivatives for the treatment of diabetes, hyperlipidemia, hypercholesterolemia and atherosclerosis | |
| DE602006019710D1 (de) | Magnesiumsalze von hmg-coa-reduktase-hemmern | |
| RU2014145102A (ru) | Комбинация | |
| RU2018110622A (ru) | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ИНГИБИТОР ГМГ-КоА РЕДУКТАЗЫ И ИНГИБИТОР АПФ |